BWA
VNDA icon

Basecamp Wealth Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Basecamp Wealth Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38K Sell
553
-140
-20% -$915 ﹤0.01% 1254
2026
Q1 		$4.79K Buy
693
+140
+25% +$1.08K ﹤0.01% 1193
2025
Q4 		$4.88K Buy
+553
New +$3.04K ﹤0.01% 1157

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Basecamp Wealth Advisors's VNDA Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Vanda Pharmaceuticals (VNDA) stake by 20% in Q2 2026, selling an estimated $915 and leaving 553 shares worth $3.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1254.

Basecamp Wealth Advisors first reported a position in VNDA in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.88K in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Basecamp Wealth Advisors held 553 shares of Vanda Pharmaceuticals worth $3.38K as of Q2 2026.
  • Basecamp Wealth Advisors sold 140 Vanda Pharmaceuticals shares in Q2 2026, an estimated $915.
  • Vanda Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1254 holding.
  • Basecamp Wealth Advisors first reported a position in Vanda Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Vanda Pharmaceuticals position peaked at $4.88K in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.